Rapid and Efficient Inactivation of SARS-CoV-2 from Surfaces using UVC Light Emitting Diode Device
This article has been Reviewed by the following groups
Listed in
- Evaluated articles (ScreenIT)
Abstract
Efforts are underway to develop countermeasures to prevent the environmental spread of COVID-19 pandemic caused by SARS-CoV-2. Physical decontamination methods like Ultraviolet radiation has shown to be promising. Here, we describe a novel device emitting ultraviolet C radiation (UVC), called NuvaWave, to rapidly and efficiently inactivate SARS-CoV-2. SARS-CoV-2 was dried on a chambered glass slides and introduced in a NuvaWave robotic testing unit. The robot simulated waving NuvaWave over the virus at a pre-determined UVC radiation dose of 1, 2, 4 and 8 seconds. Post-UVC exposure, virus was recovered and titered by plaque assay in Vero E6 cells. We observed that relative control (no UVC exposure), exposure of the virus to UVC for one or two seconds resulted in a >2.9 and 3.8 log 10 reduction in viral titers, respectively. Exposure of the virus to UVC for four or eight seconds resulted in a reduction of greater than 4.7-log 10 reduction in viral titers. The NuvaWave device inactivates SARS-CoV-2 on surfaces to below the limit of detection within one to four seconds of UVC irradiation. This device can be deployed to rapidly disinfect surfaces from SARS-CoV-2, and to assist in mitigating its spread in a variety of settings.
Article activity feed
-
SciScore for 10.1101/2021.04.20.440654: (What is this?)
Please note, not all rigor criteria are appropriate for all manuscripts.
Table 1: Rigor
Ethics IACUC: All work was carried out in the state-of-art biosafety level 3 (BSL3) laboratories at Texas Biomedical Research Institute with the approval of the Institutional Biohazard Committee. Sex as a biological variable not detected. Randomization not detected. Blinding not detected. Power Analysis not detected. Cell Line Authentication not detected. Table 2: Resources
Antibodies Sentences Resources Cells were then blocked with 2.5% bovine serum albumin (BSA) (Sigma-Aldrich, St. Louis, MO) in PBS for 1 hour at 37°C, followed by incubation with 1 µg/ml of a SARS-CoV nucleocapsid protein (NP) monoclonal antibody (mAb) 1C7C7 (Millipore-Sigma, St. Louis, MO) shown to cross-react with SARS-CoV-2 NP, diluted in 1% … SciScore for 10.1101/2021.04.20.440654: (What is this?)
Please note, not all rigor criteria are appropriate for all manuscripts.
Table 1: Rigor
Ethics IACUC: All work was carried out in the state-of-art biosafety level 3 (BSL3) laboratories at Texas Biomedical Research Institute with the approval of the Institutional Biohazard Committee. Sex as a biological variable not detected. Randomization not detected. Blinding not detected. Power Analysis not detected. Cell Line Authentication not detected. Table 2: Resources
Antibodies Sentences Resources Cells were then blocked with 2.5% bovine serum albumin (BSA) (Sigma-Aldrich, St. Louis, MO) in PBS for 1 hour at 37°C, followed by incubation with 1 µg/ml of a SARS-CoV nucleocapsid protein (NP) monoclonal antibody (mAb) 1C7C7 (Millipore-Sigma, St. Louis, MO) shown to cross-react with SARS-CoV-2 NP, diluted in 1% BSA for 1 hour at 37°C.24 After incubation with the primary mAb, cells were washed three times with PBS, and developed with the Vectastain ABC kit and DAB Peroxidase Substrate kit (Vector Laboratory, Inc., Burlingame CA) according to the manufacturers’ instructions. SARS-CoV nucleocapsid protein (NPsuggested: NoneExperimental Models: Cell Lines Sentences Resources Vero E6 cells were used to generate SARS-CoV-2 stocks and for virus titration assays. Vero E6suggested: RRID:CVCL_XD71)Software and Algorithms Sentences Resources Cells were then blocked with 2.5% bovine serum albumin (BSA) (Sigma-Aldrich, St. Louis, MO) in PBS for 1 hour at 37°C, followed by incubation with 1 µg/ml of a SARS-CoV nucleocapsid protein (NP) monoclonal antibody (mAb) 1C7C7 (Millipore-Sigma, St. Louis, MO) shown to cross-react with SARS-CoV-2 NP, diluted in 1% BSA for 1 hour at 37°C.24 After incubation with the primary mAb, cells were washed three times with PBS, and developed with the Vectastain ABC kit and DAB Peroxidase Substrate kit (Vector Laboratory, Inc., Burlingame CA) according to the manufacturers’ instructions. Millipore-Sigmasuggested: NoneVector Laboratorysuggested: None24 Viral titers were calculated as PFU/mL. Statistics: Data obtained was plotted using the GraphPad Prism v. GraphPadsuggested: (GraphPad Prism, RRID:SCR_002798)Results from OddPub: We did not detect open data. We also did not detect open code. Researchers are encouraged to share open data when possible (see Nature blog).
Results from LimitationRecognizer: An explicit section about the limitations of the techniques employed in this study was not found. We encourage authors to address study limitations.Results from TrialIdentifier: No clinical trial numbers were referenced.
Results from Barzooka: We did not find any issues relating to the usage of bar graphs.
Results from JetFighter: We did not find any issues relating to colormaps.
Results from rtransparent:- Thank you for including a conflict of interest statement. Authors are encouraged to include this statement when submitting to a journal.
- Thank you for including a funding statement. Authors are encouraged to include this statement when submitting to a journal.
- No protocol registration statement was detected.
-
